| Literature DB >> 25609421 |
Donna M Urquhart1, Yiliang Zheng2, Allen C Cheng3, Jeffrey V Rosenfeld4,5, Patrick Chan6,7, Susan Liew8,9, Sultana Monira Hussain10, Flavia M Cicuttini11.
Abstract
BACKGROUND: Recently, there has been both immense interest and controversy regarding a randomised, controlled trial which showed antibiotics to be effective in the treatment of chronic low back pain (disc herniation with Modic Type 1 change). While this research has the potential to result in a paradigm shift in the treatment of low back pain, several questions remain unanswered. This systematic review aims to address these questions by examining the role of bacteria in low back pain and the relationship between bacteria and Modic change.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25609421 PMCID: PMC4320560 DOI: 10.1186/s12916-015-0267-x
Source DB: PubMed Journal: BMC Med ISSN: 1741-7015 Impact factor: 8.775
Criteria used to assess the methodological quality of selected cohort and cross-sectional studies (Lievense et al. [5,6])
|
|
|
|
|---|---|---|
| Study population | ||
| 1 | Selection before disease was present or at uniform point | CH/CC/CS |
| 2 | Cases and controls were drawn from the same population | CC |
| 3 | Participation rate ≥80% for cases/cohort | CH/CC/CS |
| 4 | Participation rate ≥80% for controls | CC |
| 5 | Sufficient description of baseline characteristics | CH/CC/CS |
| Assessment of risk factor | ||
| 6 | Presence of bacteria was blinded | CH/CC/CS |
| 7 | Presence of bacteria were measured identical for cases and controls | CC |
| 8 | Presence of bacteria were assessed prior to the outcome | CH/CC/CS |
| Assessment of outcome | ||
| 9 | Low back pain/ Modic change was assessed identical in studied population | CH/CC/CS |
| 10 | Low back pain/ Modic change was assessed reproducibly | CH/CC/CS |
| 11 | Low back pain/ Modic change was assessed according to standard definitions | CH/CC/CS |
| Study design | ||
| 12 | Prospective design was used | CH/CC/CS |
| 13 | Follow-up time ≥2 years | CH |
| 14 | Withdrawals ≤20% | CH |
| Analysis and data presentation | ||
| 15 | Appropriate analysis techniques were used | CH/CC/CS |
| 16 | Adjusted for at least age and sex | CH/CC/CS |
CH, Applicable to cohort studies; CC, Applicable to case–control studies; CS, Applicable to cross-sectional studies; OA, Osteoarthritis.
The PEDro Scale [7] – criteria used to assess the methodological quality of selected randomised control trials
|
|
|
| |
|---|---|---|---|
| 1. Eligibility criteria were specified | |||
| 2. Subjects were randomly allocated to groups (in a crossover study, subjects were randomly allocated an order in which treatments were received) | |||
| 3. Allocation was concealed | |||
| 4. The groups were similar at baseline regarding the most important prognostic indicators | |||
| 5. There was blinding of all subjects | |||
| 6. There was blinding of all therapists who administered the therapy | |||
| 7. There was blinding of all assessors who measured at least one key outcome | |||
| 8. Measures of at least one key outcome were obtained from more than 85% of the subjects initially allocated to groups | |||
| 9. All subjects for whom outcome measures were available received the treatment or control condition as allocated or, where this was not the case, data for at least one key outcome was analysed by “intention to treat” | |||
| 10. The results of between-group statistical comparisons are reported for at least one key outcome | |||
| 11. The study provides both point measures and measures of variability for at least one key outcome | |||
| TOTAL (checked excluding eligibility criteria specified): |
Criteria list for determining the level of evidence for best evidence synthesis, adapted from Lievense et al. [6,7]
|
|
|
|---|---|
| Strong evidence | Generally consistent findings in multiple high quality cohort studies |
| Moderate evidence | Generally consistent findings in 1 high quality cohort study, >2 high quality case–control studies, or >3 high quality case–control studies |
| Limited evidence | Generally consistent findings in a single cohort study, 1 or 2 case–control studies, or multiple cross-sectional studies |
| Conflicting evidence | Inconsistent findings in <75% of the trials |
| No evidence | No studies could be found |
Evidence for a causal relationship between low virulent bacteria and low back pain according to Bradford Hill’s criteria
|
|
|
|
|---|---|---|
|
| This is an essential criterion. For a possible risk factor to be the cause of a disease it has to come before the disease. This is generally easier to establish from cohort studies but rather difficult to establish from cross-sectional or case–control studies when measurements of the possible cause and the effect are made at the same time. | There is one longitudinal study available [ |
|
| The association of a risk factor with a disease is more likely to be the cause of the disease if the association found is consistent with knowledge obtained from other sources such as animal experiments, experiments on biological mechanisms, etc. However, this criterion must be used with care because, often, the lack of plausibility may simply reflect a lack of scientific knowledge. | It is plausible for low virulent bacteria to cause chronic infection and symptoms such as low back pain. However, the bacteria isolated are also known potential contaminants. |
|
| If similar results have been found in different populations using different study designs, then the association is more likely to be causal since it is unlikely that all studies were subject to the same type of errors (chance, bias, or confounding). However, a lack of consistency does not exclude a causal association since different exposure levels and other conditions may reduce the impact of the causal factor in certain studies. | There is consistency in the results across a number of studies; however, these studies were largely all cross-sectional in design and in similar populations (i.e., those having spinal surgery for disc herniation). A study that examined a control group (consisting of patients with trauma, myeloma, scoliosis, and degenerative disc disease) found patients with low back pain (sciatica) to have more positive tissue cultures (53% [19/36]) as compared with controls (0% [0/14] |
|
| The strength of an association is measured by the size of the relative risk. A strong association is more likely to be causal than is a weak association, which could more easily be the result of confounding or bias. | In most of the identified studies there were a significant proportion of bacteria but few compared this to control groups. |
|
| Further evidence of a causal relationship is provided if increasing levels of exposure lead to increasing risks of disease. | There is limited evidence to support a dose–response relationship. |
|
| If a particular exposure increases the risk of a certain disease but not the risk of other diseases, then this is strong evidence in favour of a cause-effect relationship. However, one-to-one relationships between exposure and disease are rare and lack of specificity should not be used to say that a relationship is causal. | Similar bacterial species have been isolated in all studies, but few examined control groups. |
|
| When the removal of a possible risk factor results in a reduced risk of disease, then the likelihood that this association is causal is increased. Ideally, this should be assessed by conducting a RCT. Unfortunately, for many exposures/diseases such RCTs are just not possible in practice. | A single randomised controlled trial by Albert et al. [ |
|
| The suggested cause-effect relationship should essentially be consistent with the natural history and biology of the disease. | The relationship is consistent with the natural history and biology of an infective process. |
|
| The causal relationship will be further supported if there are similarities with other (well-established) cause-effect relationships. | Low grade infection in other sites (albeit involving prosthetic joints) may present with subacute or chronic pain and swelling. |
RCT, Randomised controlled trial.
Figure 1PRISMA flow diagram showing the flow of information through the different phases of the systematic review.
Characteristics of the 11 identified studies
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
| |||||||
|
| |||||||
| Albert [ | Cross-sectional/ cohort | 61 (27% F) | Disc herniation | Inclusions: | Yes – Type, size, and volume were graded according to the Nordic Modic Protocol | No | 78/75 |
| Age: 46.4 | Primary surgery at a single spinal level | 18 to 65 years old | |||||
| MRI-confirmed lumbar disc herniation | |||||||
| Exclusions: | |||||||
| Received antibiotic treatment within previous 2 weeks | |||||||
| Stirling [ | Cross-sectional | 36 (NA) | Discogenic radiculitis | Not specified | No | No | 78 |
| Age: NA | Microdiscectomy | ||||||
| Stirling [ | Cross-sectional | 207 (NA) | Discogenic radiculitis | Not specified | No | Yes – patients with trauma, tumour, or scoliosis | 56 |
| Age: NA | Microdisectomy | ||||||
| Agarwal [ | Cross-sectional | 52 (42% F) | Radiculopathy | Inclusions: | No | No | 78 |
| Age: 43.9 | Disc herniation | Sensory or motor symptoms in a single lumbar nerve distribution | |||||
| Lumbar microdiscectomy | |||||||
| Positive physical examination findings (positive straight leg raise test, distributional weakness, diminished deep tendon reflexes) | |||||||
| MRI lumbar spine positive for HNP | |||||||
| Exclusions: | |||||||
| Diabetes mellitus, oral steroid use in the month before surgery, other immunosuppressive medications | |||||||
| Plain radiography demonstrating severe loss of disc height | |||||||
| High grade degenerative disc disease, spondylolisthesis > grade 1 | |||||||
| History of prior lumbar surgery, multilevel symptomatic HNP or trauma | |||||||
| Red flags (progressive weakness, bowel/bladder complaints, radiographic unknown mass, unexpected weight loss) | |||||||
| Diagnosis of inflammatory arthritides, crystalline arthropathies, or other rheumatologic diseases | |||||||
| Arndt [ | Cross-sectional | 83 (59% F) | Disc degeneration | Not specified | Yes – Type 1 and 2 according to the Modic classification | No | 67 |
| Age: 41 | Lumbar disc replacement at L3-4, L4-5, or L5-S1 | ||||||
| Coscia [ | Cross-sectional | 165 (NA) | Disc herniation | Not specified | No | Yes – Five groups, including cervical disc herniations, lumbar disc herniations, lumbar discogenic pain, deformity, and control | 78 |
| Age: NA | Surgery not specified | ||||||
| Ben-Galim [ | Cross-sectional | 30 (40% F) | Disc herniation | Exclusions: | No | No | 67 |
| Age: 46.4 (NA) | Lumbar discectomy | Individuals who had been treated with antibiotics in the 2 months preceding the study | |||||
| Those who had undergone back surgery | |||||||
| History of intradiscal injections | |||||||
| Fritzell [ | Cross-sectional | 10 (40% F) | Disc herniation | Not stated | No | No | 67 |
| Age (range): 20–47 | Surgery not specified | ||||||
| Carricajo [ | Cross-sectional | 54 (41%) | Disc herniation | Not stated | No | No | 67 |
| Age: 44.8 (NA) | Surgery not specified | ||||||
| Albert [ | Randomised controlled trial | Intervention group: | Chronic LBP (>6 months) occurring after a previous disc herniation and who also had Modic type 1 changes in the vertebrae adjacent to the previous herniation | Inclusions: | Yes – Modic Type 1 only; size and volume of Modic changes were graded according to the Nordic Modic Protocol | Yes | 100 |
| Aged between 18 and 65 years | |||||||
| 90 (58.2% F) | MRI-confirmed disc herniation L3/L4 or L4/L5 or L5/S1 within the preceding 6–24 months | ||||||
| Age: 44.7 (10.3) | |||||||
| Placebo group: | Lower back pain of >6 months duration | ||||||
| 72 (58.2% F) | Nil surgery | Modic type 1 changes adjacent to the previously herniated disc on repeat MRI | |||||
| Age: 45.5 (9.2) | Exclusions: | ||||||
| Allergy to antibiotics | |||||||
| Current pregnancy or lactation | |||||||
| Any kidney disease | |||||||
| Pending litigation | |||||||
|
| |||||||
| Wedderkopp [ | Cross-sectional | 24 (58% F) | ‘Persistent LBP’ Modic type I changes in at least 1 vertebra | Inclusion: Type 1 Modic changes on MRI | Yes – Modic Type 1 only | No | 67 |
| Age: 43 (NA) | |||||||
| No surgery performed | |||||||
HNP, Herniated nucleus pulposus; LBP, Low back pain.
Methods used for bacteria identification and to minimize contamination and prevalence, and type of bacteria identified
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| Albert [ | Open | All scalpels flamed before use as extra precaution | 7 days with subsequent 1 day of subculture | Culture, PCR | 28/61 (46%) |
| Analytical profile index biochemical analysis using Rapid ID 32A kit (bioMerieux) and PCR amplification of 16S rDNA | 78 |
| Disc material | Gram-positive cocci: 14% | |||||||
| Five specimens | ||||||||
| Coagulase-negative | ||||||||
| Stirling [ | Open | Stringent aseptic precautions taken to minimise risk of contamination | 7 days | Culture, serology | 19/36 (53%) |
| Microscopy of Gram-stained smears of tissue samples | 78 |
| Disc material | CN staphylococci: 11% | |||||||
| Not stated | ||||||||
| Corynebacterium propinquum: 5% | ||||||||
| Stirling [ | Open | Not stated | 7 days | Culture, serology | 76/207 (37%) |
| Microscopy of Gram-stained smears of tissue samples | 56 |
| Disc material | CN staphylococci: 14% | |||||||
| Not stated | Propionibacteria: 10.5% | |||||||
| Agarwal [ | Open | Disc material retained in a closed sterile sample cup | 5 days | Culture | 10/52 (19.2%) |
| Not stated | 78 |
| Disc material | Peptostreptococci: 10% | |||||||
| Not stated | Staphylococci aureus: 10% | |||||||
| CN staphylococci: 10% | ||||||||
| Arndt [ | Open | Disc structures stored in sterile syringes filled with physiological saline solution, care was taken to avoid contamination during conditioning process of biopsy | Blood agar, Drigalski agar: 24 h | Culture | 40/83 (48.2%) |
| Not stated | 67 |
| Disc material | Polyvitex chocolate agar: 4 days | CN staphylococci: 40% | ||||||
| 1 in 1st 25 disk replacements; 3 in following 58 | Blood agar supplemented with hemin: 5 days | CN bacilli: 7.5% | ||||||
| Peptone glucose yeast broth: 10 days | ||||||||
| Bactec Peds Plue bottle with fructooligosaccharide nutritional supplement: 7 days | ||||||||
| Coscia [ | Open | Specimens were obtained sterilely immediately at the time of surgical excision | Cultured using extended duration incubation techniques (repeated subcultures up to several weeks duration) | Culture | 16/30 (53.3%) | Staphylococcus: 36% | Not stated | 78 |
| Disc material |
| |||||||
| Not stated | ||||||||
| Ben-Galim [ | Open | Samples are processed and cultured intraoperatively under stringent, sterile operating theatre conditions, culture mediums were warmed to room temperature before each operation | 2 weeks | Culture | 2/30 (6.7%) | CN staphylococci: 100% | Not stated | 67 |
| Disc material | ||||||||
| Four pieces (disc material dissected into four pieces) | ||||||||
| Fritzell [ | Open | Samples taken openly (no needle), all operations except for one were performed through a microscope with use of bipolar diathermy, assuring a very ‘dry’ operation field | Not applicable | PCR | (PCR) | (PCR) | Not stated | 67 |
| Disc material | 2/10 (20%) | Bacillus cereus: 50% | ||||||
| Two – one from annulus fibrosus and one from nucleus pulposus | Citrobacterbraaki/freundi: 50% | |||||||
| Carricajo [ | Open | Obtained under aseptic conditions | One horse-blood agar, two chocolate PolyVitex agar: 10 days | Culture | 12/54 (22%) |
| Not stated | 67 |
| One Schaedler medium: 20 days | ||||||||
| Disc material, muscle, ligamentum flavum | Anaerobic streptococci: 8% | |||||||
| Three – muscle, ligamentum flavum, herniated intervertebral discs | ||||||||
| Wedderkopp [ | Needle | Obtained with sterile technique | 2 weeks | Culture | 2/24 (8.3%) | Staph epidermidis: 50% | Not stated | 67 |
| CN staphylococci: 50% | ||||||||
| Vertebral body | ||||||||
| One – at site of Modic Type 1 change |
Studies examining the relationship between the presence of low virulent bacteria and modic changes
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Albert [ | Randomised controlled trial | Treatment group: | Chronic LBP (>6 months) occurring after a previous disc herniation and who also had Modic type 1 changes in the vertebrae adjacent to the previous herniation | Type, size, and volume graded according to the Nordic Modic Protocol | Modic changes: Treatment group: 142 (92.2%) | 100 |
| 90 (58.2% F) | Placebo group: 130 (97%) | |||||
| Grade 1 Modic changes: Treatment group: 10.4%; Placebo group: 28.8% | ||||||
| Age: 44.7 (10.3) |
| |||||
| Placebo group: | At 1-year follow-up, 10 patients in both groups demonstrated no Modic changes | |||||
| 72 (58.2% F) | ||||||
| Treatment group: Significant decrease in volume; volume 2–4 were reduced to volume 1 ( | ||||||
| Age: 45.5 (9.2) | Placebo group: Not observed | |||||
| Albert [ | Cohort | 61 (27% F) | Disc herniation | Type, size, and volume graded according to the Nordic Modic Protocol | Discs (anaerobic bacteria): 80% developed new Modic changes in the vertebrae adjacent to the previous disc herniation. Discs (Aerobic): No new; MC discs (negative cultures): 44% new MC | 78 |
| Age: 46.4 | ||||||
| The association between an anaerobic culture and new MCs was significant | ||||||
| 5.60 (95% CI 1.51–21.95), ( | ||||||
| Arndt [ | Cross-sectional | 83 (59% F) | Disc degeneration | Modic changes (Type 1 and 2) | There was no significant association between Modic changes and positive cultures ( | 67 |
| Age: 41 | ||||||
| Wedderkopp [ | Cross-sectional | 24 (58% F) | No clinical symptoms; Modic type I changes in at least 1 vertebra | Type 1 Modic changes only | There was no evidence of bacteria in vertebrae with Modic type 1 changes, with only 2/24 patients yielding bacteria. | 67 |
| Age: 43 (NA) |
Figure 2Forest plot showing the proportion of positive cultures in the nine studies examining the presence of bacteria in disc material in patients undergoing spinal surgery.